Evidence map›Paper›PMID 36380614›Full record

ArticleHormone research in paediatrics2023

Prospective Test Performance of Nonfasting Biomarkers to Identify Dysglycemia in Children and Adolescents.

Mary Ellen Vajravelu, Emily Hirschfeld, Acham Gebremariam, Charles F Burant, William H Herman, Karen E Peterson, Jennifer L Meijer, Joyce M Lee

Open access · greenAbstract read
In one paragraph

Article in Hormone research in paediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mary Ellen VajraveluDivision of Pediatric Endocrinology, Diabetes and Metabolism, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Emily HirschfeldSusan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Acham GebremariamSusan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Charles F BurantDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
William H HermanDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Karen E PetersonDepartment of Nutritional Sciences, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Jennifer L MeijerDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Joyce M LeeSusan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
University of Michigan · USDartmouth–Hitchcock Medical Center · USUniversity of Pittsburgh · US

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
Strategic Vision & Impact on Environmental HealthP30ES017885 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Dana Dolinoy · 2011 to 2026
$21.3M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Joyce Lee · 2010 to 2026
$20.3M
Career Development Program in Pediatric Diabetes Research (K12) at CHOPK12DK094723 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI WILLI, STEVEN M · 2011 to 2020
$3.6M
Conventional and Metabolomic Predictors of Pediatric Prediabetes & Insulin ResistR01HD074559 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LEE, JOYCE · 2014 to 2018
$2.7M
Target self-regulation to promote adherence and health behaviors in childrenUH3HD087979 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FREDERICKS, EMILY MACDONALD, MILLER, ALISON L · 2018 to 2019
$2.1M
Behavioral Economics for Activity Motivation in Adolescents and Young Adults with Prediabetes and Type 2 DiabetesK23DK125719 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VAJRAVELU, MARY ELLEN · 2020 to 2023
$789k
NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR002240NICHD NIH HHS R01 HD074559NICHD NIH HHS UH3 HD087979NIDDK NIH HHS K12 DK094723NIDDK NIH HHS K23 DK125719NIDDK NIH HHS P30 DK020572NIDDK NIH HHS P30 DK089503NIEHS NIH HHS P30 ES017885
6 · The paper itself

Abstract

introductionTest performance screening measures for dysglycemia have not been evaluated prospectively in youth. This study evaluated the prospective test performance of random glucose (RG), 1-h nonfasting glucose challenge test (1-h GCT), hemoglobin A1c (HbA1c), fructosamine (FA), and 1,5-anhydroglucitol (1,5-AG) for identifying dysglycemia.

methodsYouth ages 8-17 years with overweight or obesity (body mass index, BMI, ≥85th percentile) without known diabetes completed nonfasting tests at baseline (n = 176) and returned an average of 1.1 years later for two formal fasting 2-h oral glucose tolerance tests. Outcomes included glucose-defined dysglycemia (fasting plasma glucose ≥100 mg/dL or 2-h plasma glucose ≥140 mg/dL) or elevated HbA1c (≥5.7%). Longitudinal test performance was evaluated using receiver-operating characteristic (ROC) curves and calculation of area under the curve (AUC).

resultsGlucose-defined dysglycemia, elevated HbA1c, and either dysglycemia or elevated HbA1c were present in 15 (8.5%), 11 (6.3%), and 23 (13.1%) participants at baseline, and 16 (9.1%), 18 (10.3%), and 28 (15.9%) participants at follow-up. For prediction of glucose-defined dysglycemia at follow-up, RG, 1-h GCT, and HbA1c had similar performance (0.68 (95% CI: 0.55-0.80), 0.76 (95% CI: 0.64-0.89), and 0.70 (95% CI: 0.56-0.84)), while FA and 1,5-AG performed poorly. For prediction of HbA1c at follow-up, baseline HbA1c had strong performance (AUC 0.93 [95% CI: 0.88-0.98]), RG had moderate performance (AUC 0.67 [95% CI: 0.54-0.79]), while 1-h GCT, FA, and 1,5-AG performed poorly.

conclusionHbA1c and nonfasting glucose tests had reasonable longitudinal discrimination identifying adolescents at risk for dysglycemia, but performance depended on outcome definition.

Indexed as

Blood GlucosePrediabetic StateAdolescentBiomarkersChildGlycated HemoglobinHumansProspective StudiesBiomarkersBlood GlucoseGlycated HemoglobinAdolescentGlycated hemoglobin AInsulinType 2 diabetes mellitus

Identifiers

PMID36380614
PMCPMC10183477
OpenAlexW4309165770

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.